Ubrogepant

• Migraine
• Migraine with Aura
• Acute Migraine Treatment

Ubrogepant, marketed as Ubrelvy, is an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine attacks with or without aura in adults. It is one of two members of the gepant class approved for acute migraine relief in the United States, the other being rimegepant, and represents a major addition to the migraine pharmacopeia by offering effective pain relief without the vasoconstrictive effects of triptans. Patients who cannot use triptans because of cardiovascular contraindications, or who have had inadequate response to or intolerance of triptans, now have a mechanistically distinct option. Ubrogepant is taken at the onset of a migraine attack and works within hours, with a tolerable side effect profile and a lower headache-recurrence rate than was sometimes seen with triptans. It is not used for migraine prevention, where related drugs like erenumab and the small-molecule rimegepant fill that role.

Mechanism of Action

During a migraine attack, calcitonin gene-related peptide is released from sensory neurons in the trigeminal ganglion and trigeminocervical complex. CGRP causes potent dilation of intracranial arteries, sterile neurogenic inflammation around meningeal vessels, mast cell degranulation, and sensitization of central trigeminal pathways. Together these events produce the throbbing pain, photophobia, phonophobia, nausea, and allodynia that characterize migraine. Ubrogepant is a small-molecule selective antagonist of the canonical CGRP receptor, a heterodimer of calcitonin receptor-like receptor and receptor activity-modifying protein 1.

By occupying this receptor, ubrogepant prevents endogenous CGRP from initiating downstream G-protein-coupled signaling that drives vasodilation and pain transmission. Because the molecule does not directly cause vasoconstriction, it is safe in patients with coronary artery disease, history of myocardial infarction, stroke, peripheral arterial disease, uncontrolled hypertension, and pregnancy considerations that exclude triptan use. Ubrogepant reaches peak plasma concentration in about 1.5 hours and has a half-life of 5 to 7 hours, allowing meaningful pain relief within 2 hours and persistent freedom from pain for many patients at 24 hours. It is metabolized primarily by hepatic CYP3A4 and is a substrate of P-glycoprotein and BCRP transporters, which explains its drug interaction profile. The CGRP-targeted monoclonal antibodies including erenumab, galcanezumab, and fremanezumab work on the same pathway but provide month-long preventive blockade rather than acute relief. More information on migraine treatment is available from the American Academy of Neurology.

Clinical Use

Within the migraine acute treatment algorithm, ubrogepant is positioned as either a first-line or second-line acute therapy depending on patient characteristics. Triptans such as sumatriptan remain commonly used and inexpensive first-line options for patients without cardiovascular contraindications. Ubrogepant is preferred as initial therapy for patients with established cardiovascular disease, uncontrolled hypertension, history of stroke, or other vasoconstrictor cautions; for patients who have not responded to or have not tolerated two or more triptans; and for those who experience medication-overuse headache from frequent triptan or NSAID use, since gepants are not associated with medication-overuse headache.

Clinical trials, including ACHIEVE I and II, demonstrated that ubrogepant produces freedom from pain at 2 hours in approximately 19 to 21 percent of patients (versus 12 to 14 percent with placebo) and freedom from the most bothersome migraine symptom in 38 to 39 percent. Pain relief at 2 hours is achieved in roughly 60 percent. Many patients also experience sustained pain freedom from 2 through 24 hours. The medication can be taken at any phase of the attack but tends to work better the earlier it is used relative to onset. It can be combined with NSAIDs such as ibuprofen and naproxen, acetaminophen, and antiemetics like ondansetron for breakthrough nausea. Use alongside CGRP-targeted monoclonal antibodies for prevention is generally compatible. The newer ditan lasmiditan is a non-vasoconstrictive serotonin 5-HT1F agonist with similar cardiovascular advantages but considerable CNS sedation that limits driving for hours. Our neurologic team helps patients select among these options based on attack pattern, comorbidities, and response.

How to Take It

Ubrogepant is supplied as 50 mg and 100 mg tablets. The recommended initial dose is 50 mg or 100 mg taken orally as soon as a migraine attack begins, with or without food. If the headache returns or the response is inadequate after at least 2 hours, a second dose may be taken; the maximum dose in 24 hours is 200 mg. Patients should not exceed this limit and should not take ubrogepant on more than 8 days per month, as repeated frequent use suggests inadequate prevention and risks transformation to chronic daily headache patterns.

Tablets are swallowed whole with water. There is no specific food restriction, although a high-fat meal can delay absorption modestly. If a patient typically vomits early in an attack, taking ubrogepant at the very first sensation of pain or aura helps ensure absorption before vomiting occurs; using an antiemetic concurrently is reasonable. Storage is at room temperature, away from moisture and heat. The first dose may produce mild somnolence, dry mouth, or nausea; these are usually mild and short-lived. Most patients tolerate the second dose, if needed, similarly to the first. Caution with driving until effects on alertness are known is wise, especially with the 100 mg dose. Ubrogepant should not be combined with any strong CYP3A4 inhibitor; this is a contraindication, not just a caution.

Monitoring and Follow-Up

Ubrogepant does not require routine laboratory monitoring. Clinical follow-up focuses on response and use pattern. Patients are encouraged to track each attack: time of onset, time of dosing, time to meaningful pain relief, time to pain freedom, recurrence within 24 hours, presence of associated symptoms (nausea, photophobia, phonophobia), and any second dose taken. This headache diary informs whether to continue ubrogepant, escalate to the 100 mg dose, switch to a different acute agent, or add a preventive medication.

A key red flag in any acute migraine treatment is escalating frequency of attacks or escalating use of acute medication. If a patient is using ubrogepant on more than 8 days per month, or any acute migraine medication on more than 10 to 15 days per month depending on type, preventive therapy should be considered to avoid medication-overuse headache patterns. Failure to improve within 2 hours despite optimal dosing in a typical attack pattern, particularly if accompanied by new neurologic features (significant visual loss, weakness, severe sudden-onset headache, fever, neck stiffness), warrants urgent evaluation to rule out secondary causes such as subarachnoid hemorrhage, stroke, or meningitis. Blood pressure should be reasonably controlled before starting any migraine therapy. Liver enzymes do not need routine surveillance for ubrogepant in healthy patients. Worsening of underlying chronic headaches should prompt reevaluation of the overall plan.

Special Populations

Elderly patients have not been extensively studied in dedicated trials, but no specific dose adjustment is required based on age alone. Hepatic impairment requires attention: in mild to moderate hepatic impairment, the initial dose is 50 mg with careful consideration of a second dose; in severe hepatic impairment, ubrogepant should be avoided. Renal impairment is generally well tolerated; for severe renal impairment (eGFR 15 to 29 mL/min/1.73 m squared), the 50 mg dose is recommended and the second dose within 24 hours should be avoided. Ubrogepant has not been studied in end-stage renal disease and should be avoided in that setting.

Pregnancy data are limited; animal studies showed no harm at clinically relevant exposures, but human data are insufficient to fully characterize risk. Many migraineurs experience improvement during pregnancy, especially in the second and third trimesters, and non-pharmacologic strategies are emphasized first. Acetaminophen is generally the preferred analgesic in pregnancy. Lactation: it is unknown whether ubrogepant is excreted in breast milk; the developmental and health benefits of breastfeeding should be weighed against any potential risk. Pediatric safety and efficacy have not been established. Patients on strong CYP3A4 inhibitors (including ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice in significant amounts) should not take ubrogepant. With moderate CYP3A4 inhibitors, the initial dose is reduced to 50 mg and a second dose within 24 hours is avoided. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort) significantly reduce ubrogepant exposure and concomitant use should be avoided.

When to Contact Your Doctor

Call the office for headaches that are different from your usual migraine pattern, including the worst headache of your life, sudden severe (thunderclap) onset, headache with fever or neck stiffness, headache after head trauma, new neurologic symptoms (weakness, slurred speech, severe visual loss, confusion, seizure), or headache that does not respond at all to ubrogepant despite proper dosing. Persistent or escalating use of acute migraine medication on more than 8 days per month should prompt a discussion about preventive therapy. Allergic reactions including rash, swelling of the lips or face, or difficulty breathing require emergency care.

New chest pain, palpitations, severe abdominal pain, or jaundice should be evaluated. Pregnancy or plans for pregnancy should be discussed before continued use. For evaluation of recurrent migraines, optimization of acute therapy, or consideration of CGRP-targeted treatment, contact us or schedule a visit. Detailed dosing tables, drug interactions, and frequently asked questions appear on this page below.